Comparative Effectiveness of Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Diabetic Retinopathy Management
International Journal of Current Pharmaceutical Review and Research · 31.03.2026 · 18 (03)
DOI: 10.25258/ijcpr.18.3.287 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.03.2026. Verfasst von Sneha Raj und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard first-line treatment for vision-threatening diabetic macular edema and selected severe diabetic retinopathy phenotypes, but comparative outcomes among bevacizumab, ranibizumab, and aflibercept remain clinically important in resource-variable settings.
Aim
To compare functional, anatomic, and short-term safety outcomes following intravitreal bevacizumab, ranibizumab, and aflibercept in diabetic retinopathy requiring anti-VEGF treatment.
Methods
A journal-style comparative cohort draft was structured for Government Medical College & Hospital, Bettiah, West Champaran, Bettiah, Bihar, India, over 1st March 2025 to 20th February 2026, using a synthetic dataset of 150 patients (50 per treatment arm) to model a realistic anti-VEGF comparison. Outcomes included ETDRS visual acuity, central macular thickness (CMT), responder rates, injection burden, and ocular adverse events over 6 months.
Results
Baseline demographic and ocular characteristics were comparable among groups. By month 6, mean ETDRS gain was 10.22 ± 4.12 letters with bevacizumab, 11.45 ± 3.13 with ranibizumab, and 15.38 ± 3.31 with aflibercept (p
Zitieren
APA
Raj, S., Ravi, A., Kumar, S., & Keshav, P. K. (2026). Comparative Effectiveness of Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Diabetic Retinopathy Management. International Journal of Current Pharmaceutical Review and Research, 18(03). https://doi.org/10.25258/ijcpr.18.3.287
Vancouver
Raj S, Ravi A, Kumar S, Keshav PK. Comparative Effectiveness of Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Diabetic Retinopathy Management. International Journal of Current Pharmaceutical Review and Research. 2026;18(03). doi:10.25258/ijcpr.18.3.287
BibTeX
@article{Raj2026,
author = {Raj, Sneha and Ravi, Alka and Kumar, Sudhir and Keshav, Prakash Kumar},
title = {Comparative Effectiveness of Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Diabetic Retinopathy Management},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {03},
doi = {10.25258/ijcpr.18.3.287}
}
EUVIMED